GlassScriptPhysician profile
Amit Bansal
NPI 1356736433
$13,384.66
in general payments reported to CMS, 2019-2025
50 companies · $8,360 in 2025
The $8,360 reported for 2025 was more than what 87% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $257 · 2020: $99.99 · 2021: $213 · 2022: $845 · 2023: $1,276 · 2024: $2,334 · 2025: $8,360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,555 · Food and Beverage: $2,920 · Long Term Medical Supply Or Device Loan: $1,280 · Travel and Lodging: $954 · Education: $261.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,555.00 |
| Food and Beverage | $2,919.83 |
| Long Term Medical Supply Or Device Loan | $1,279.73 |
| Travel and Lodging | $954.25 |
| Education | $260.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $7,883.28 | 2025 | |
| Novartis Pharmaceuticals Corporation | $1,728.80 | 2022-2025 | Sandostatin |
| Pfizer INC. | $345.02 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $342.44 | 2019-2023 | Opdualag, Opdivo |
| Janssen Biotech, INC. | $329.97 | 2022-2024 | Darzalex, Imbruvica, Tecvayli |
| Astellas Pharma US INC | $217.77 | 2022-2024 | Xtandi, Padcev |
| Seagen INC. | $216.50 | 2022-2023 | Padcev, Tukysa |
| Genzyme Corporation | $197.29 | 2019-2024 | |
| Abbvie INC. | $172.91 | 2019-2024 | Venclexta, Creon, Linzess |
| Amgen INC. | $150.54 | 2019-2023 | Blincyto, Kyprolis |
| Exelixis INC. | $139.88 | 2024 | Cabometyx |
| Eisai INC. | $103.77 | 2022-2025 | |
| Epizyme, INC. | $99.00 | 2021 | |
| Sobi, INC | $90.95 | 2023 | |
| Lilly USA, LLC | $82.93 | 2023-2025 | Jaypirca, Verzenio, Retevmo |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $76.04 | 2022-2024 | Calquence, Enhertu |
| Pharmacyclics LLC, An Abbvie Company | $73.89 | 2019-2023 | Imbruvica |
| Inari Medical, INC. | $67.08 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Daiichi Sankyo INC. | $67.02 | 2023-2025 | Enhertu |
| Glaxosmithkline, LLC. | $66.27 | 2022-2023 | Zejula |
| Merck Sharp & Dohme LLC | $62.53 | 2022-2023 | Keytruda |
| Pharmacosmos Therapeutics INC. | $62.09 | 2022-2023 | Monoferric |
| Alexion Pharmaceuticals, INC. | $57.06 | 2023-2024 | Ultomiris |
| Incyte Corporation | $55.01 | 2019-2023 | Jakafi |
| Sirtex Medical INC | $54.96 | 2022 | |
| Gilead Sciences, INC. | $52.82 | 2023-2025 | Trodelvy |
| Genentech USA, INC. | $52.60 | 2022 | |
| Mirati Therapeutics, INC. | $49.29 | 2023-2024 | Krazati |
| Array Biopharma INC | $48.66 | 2024-2025 | Mektovi, Braftovi, Lorbrena |
| Bayer Healthcare Pharmaceuticals INC. | $46.45 | 2024-2025 | |
| Adaptive Biotechnologies Corporation | $40.09 | 2023-2024 | Clonoseq |
| Celgene Corporation | $35.21 | 2023 | Pomalyst, Reblozyl |
| Tempus Ai, INC | $33.65 | 2024 | |
| Stemline Therapeutics INC. | $30.84 | 2023 | Orserdu |
| Kite Pharma, INC. | $27.99 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.91 | 2024 | Fruzaqla |
| Aveo Pharmaceuticals, INC. | $20.00 | 2025 | |
| Coherus Oncology, INC. | $19.80 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $17.85 | 2023 | Tazverik |
| Acrotech Biopharma INC. | $16.92 | 2023 | Beleodaq |
| Servier Pharmaceuticals LLC | $16.90 | 2023 | |
| Alnylam Pharmaceuticals INC. | $15.46 | 2022 | |
| Pharmaessentia USA Corporation | $15.03 | 2023 | Besremi |
| Morphosys, US INC. | $14.90 | 2022 | |
| Beigene USA, INC. | $13.66 | 2022 | |
| Myriad Genetic Laboratories, INC. | $13.59 | 2022 | |
| Kyowa Kirin, INC. | $13.06 | 2023 | Poteligeo |
| Novocure INC. | $12.58 | 2021 | |
| Rigel Pharmaceuticals, INC. | $11.40 | 2023 | Tavalisse, Rezlidhia |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amit Bansal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.